The Asia Pacific Autoinjectors Market would witness market growth of 19.1% CAGR during the forecast period (2020-2026).
Most of the autoinjectors are single-use, disposable, spring-loaded syringes. The autoinjectors are designed in such a way that it makes them easy to use and are planned for self-administration by patients, or delivered by even untrained personnel. The place of injection mainly depends on the drug-loaded, but it is usually administered into either thigh or buttocks. Auto-injectors are favored over conventional devices because they allow efficient and enhanced drug delivery even in new formulations. The advancement of technology in products are estimated to boost growth.
Market growth is mainly driven by the increasing incidences of targeted therapies, the increasing occurrence of anaphylaxis, growing inclination for self-administration of drugs. Further, the usability benefits, the growing number of governing approvals, and the accessibility of standard versions of autoinjectors, favorable settlements pertaining to the autoinjectors is fuelling the market. In addition, government’s provision as well as technological advancements are likely to turn this market more opportunistic. The patent termination of biologics is also anticipated to deliver growth opportunities for the market.
The growth of the market in the Asia Pacific market is largely due to the large number of patients suffering from chronic allergies and diabetes as well as increasing healthcare expenditure. This in turn has drawn a number of key auto-injector device manufacturers to this region. These companies are showing more presence in the Asia Pacific market via several approaches, including partnering with local pharmaceutical companies and establishing sales offices.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments covered in the Report:
• Disposable autoinjectors
• Reusable autoinjectors
• Rheumatoid Arthritis
• Multiple Sclerosis
• Other Applications
By End Use
• Hospitals & Clinics
• Home care settings
• South Korea
• Rest of Asia Pacific
• Eli Lilly and Company
• GlaxoSmithKline PLC (GSK)
• Merck Group
• Sanofi S.A.
• Becton, Dickinson and Company
• Teva Pharmaceuticals Industries Ltd.
• Amgen, Inc.
• Ypsomed AG
• AbbVie, Inc.
• Biogen, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the pharmaceutical contract development and manufacturing organization (CMO) market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals and HAUPT Pharma AG. The global pharmaceutical...
Forecasts by Type (Modular Manufacturing, Data-Driven Manufacturing, Others), End-user (Pharma Companies, CMOs) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Flexible Manufacturing Companies AND COVID-19 Recovery Scenarios Increased Focus on Reducing Manufacturing Costs The pharmaceutical...
Generics Global Industry Almanac - Market Summary, Competitive Analysis and Forecast to 2025 Summary Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2016-20, and forecast to 2025). The profile also contains...
The global pharmaceutical contract development and manufacturing market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in...
The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the...
The Indian CMO market is expected to register a CAGR of 13.3% during the period of 2021 - 2026. The rise in demand for injectable drugs, especially in cancer research, will upwardly trend the Indian pharmaceutical contract manufacturing market. Injectable drugs offer higher returns as compared to other drug formulation types. Therefore, higher...
The European Pharmaceutical Logistics Market is expected to grow at a CAGR of more than 4% during the forecast period. The market growth can be seen as a result of Covid-19, with an increase in pharmaceutical product imports (USD 361 billion) and exports (USD 524 billion) in the year 2020. Logistics is an essential segment of supply...
The global Raman spectroscopy market is projected to reach USD 861 million by 2026 from an estimated USD 602 million in 2021, at a CAGR of 7.4% from 2021 to 2026. The Rise in adoption of Raman spectroscopy in clinical applications and advancement in utilization of Raman spectroscopic techniques for catalysts and catalytic reactions are among...
The global pharmaceutical CMO market was valued at USD 120.29 billion in 2020, and it is expected to reach USD 195.70 billion by 2026, registering a CAGR of 7.85% from 2021 to 2026. COVID-19 pandemic has had a beneficial effect on contract manufacturing services overall. There were multiple opportunities for CMOs in clinical trial manufacturing,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.